Genentech to Present New Data on Targeted Cancer Medicines at ASCO Meeting

At the upcoming 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), Genentech, a leading biotechnology company, will present new data on its targeted cancer medicines that may be used in several different cancer types. The meeting, taking place June 4 to 8 in Chicago, will feature approximately 400 abstracts showcasing Genentech and Roche's cancer medicines and investigational agents across 30 cancer types.

Key Takeaways:

• Genentech will present new data on Avastin (bevacizumab) in ovarian cancer, including late-breaking Phase III data (GOG 0218) and new data on its use in multiple lines of therapy in colorectal cancer.
• The company will also present Phase III data (PRIMA) on the maintenance use of Rituxan (rituximab) in follicular lymphoma, an incurable cancer that requires ongoing treatment.
• Additionally, Genentech will share Phase Ib/II preliminary efficacy, safety, and tolerability data on a novel combination of HER2-targeted medicines, including trastuzumab-DM1 (T-DM1) and pertuzumab, in previously treated women with HER2-positive breast cancer.
• The presentations will provide valuable insights into the potential benefits and limitations of Genentech's targeted cancer medicines, including who may benefit most from treatment and how best to use these medicines.
• Pascal Soriot, COO of Roche's Pharmaceuticals Division, emphasized the company's commitment to advancing cancer treatment options and its eagerness to share data on pipeline medicines that may offer new hope for patients.

Statistics:

• 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents will be presented at the ASCO meeting.
• The presentations will cover 30 different cancer types.
• The data to be presented include late-breaking Phase III results, Phase III trials, and Phase Ib/II preliminary efficacy and safety data.
• Avastin (bevacizumab) has been used to treat approximately millions of people with cancer worldwide.

Sources:

• Genentech, Inc.
• American Society of Clinical Oncology (ASCO)
• Roche Pharmaceuticals Division